Land: Nederland
Språk: nederlandsk
Kilde: CBG-MEB (College ter Beoordeling van Geneesmiddelen)
LEVETIRACETAM 100 mg/ml
Teva Nederland B.V. Swensweg 5 2031 GA HAARLEM
N03AX14
LEVETIRACETAM 100 mg/ml
Concentraat voor oplossing voor infusie
AZIJNZUUR (E 260), GECONCENTREERD ; NATRIUMACETAAT 3-WATER (E 262) ; NATRIUMCHLORIDE ; STIKSTOF (HEAD SPACE) (E 941) ; WATER VOOR INJECTIE,
Intraveneus gebruik
Levetiracetam
Hulpstoffen: AZIJNZUUR (E 260), GECONCENTREERD; NATRIUMACETAAT 3-WATER (E 262); NATRIUMCHLORIDE; STIKSTOF (HEAD SPACE) (E 941); WATER VOOR INJECTIE;
2011-12-29
Levetiracetam, NL/H/2194/001, 23.05.23 1 rvg 108443 EU PIL IB/025 met NL info-tracked PACKAGE LEAFLET: INFORMATION FOR THE PATIENT LEVETIRACETAM 100 MG/ ML TEVA, CONCENTRAAT VOOR OPLOSSING VOOR INFUSIE levetiracetam READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU OR YOUR CHILD START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. Whatis and what it is used for 2. What you need to know before you are given Les hele dokumentet3. How is given 4. Possible side effects 5. How to store 6. Contents of the pack and other information 1. WHAT IS AND WHAT IT IS USED FOR Levetiracetam is an antiepileptic medicine (a medicine used to treat seizures in epilepsy). is used: • on its own in adults and adolescents from 16 years of age with newly diagnosed epilepsy, to treat a certain form of epilepsy. Epilepsy is a condition where the patients have repeated fits (seizures). Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation). Levetiracetam has been given to you by your doctor to reduce the number of fits. • as an add-on to other antiepileptic medicines to treat: ▪ partial onset seizures with or without generalisation in adults, adolescents and children from 4 years of age ▪ myoclonic seizures (short, shock-like jerks of a muscle or group of muscles) in adults and adolescents from 12 years of age with juven
Levetiracetam, NL/H/2194/001, 23.05.23 Rvg 108443 EU SPC IB/025 met NL info-tracked SUMMARY OF PRODUCT CHARACTERISTICS 1. NAAM VAN HET GENEESMIDDEL Levetiracetam 100 mg/ ml Teva, concentraat voor oplossing voor infusie 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains 100 mg of levetiracetam. Each 5 ml vial contains 500 mg of levetiracetam. Excipient with known effect: Each vial contains 19.1 mg of sodium For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion. Clear, colourless, concentrate. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONSis indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy. Les hele dokumentetis indicated as adjunctive therapy • in the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy. • in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy. • in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy. concentrate is an alternative for patients when oral administration is temporarily not feasible. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology therapy can be initiated with either intravenous or oral administration. Conversion to or from oral to intravenous administration can be done directly without titration. The total daily dose and frequency of administration should be maintained. _Partial onset seizures _ Levetiracetam, NL/H/2194/001, 23.05.23 Rvg 108443 EU SPC IB/025 met NL info-tracked The recommended dosing for monotherapy (from 16 years of age) and adjunctive therapy is the same; as outlined below. _ _ _All indications _ _Adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg